How Lipid Rafts Organize GPCR Signaling

Scientific Abstract

The classical model of GPCR regulation, in which GRK mediated phosphorylation drives receptor desensitization, has been cracking for years. Keyvan Sedaghat's doctoral work on the D1 dopamine receptor offers a clear example: a receptor stripped of its phosphorylation sites still desensitized, and did so even more efficiently than the wild type receptor. The same work showed that GRK2 and GRK3, often assumed to do the same job, produce distinct desensitization profiles.

The conversation follows how that attention to exceptions extended to membrane organization. Sedaghat discusses the compartmentalization of GPCR signaling in lipid rafts, including work linking G alpha subunit localization to depression and antidepressant response, and the creation of 7TMR RAFT, a freely available database of receptors associated with lipid rafts and caveolae. His fascination with membrane microdomains began with a DVD of single molecule imaging handed out at a GPCR retreat, a disc he still keeps at home.

The discussion also covers the limits of computational prediction in receptor pharmacology, the difficulty of altering neuronal lipid composition in vivo, and the extraoral roles of bitter taste receptors as potential targets in cancer, asthma, and cardiovascular disease.

About Keyvan

Sedaghat is a lecturer in pharmacology and biomedical science at a private institute in Toronto that prepares internationally trained pharmacists for licensure through the Pharmacy Examining Board of Canada. He studied pharmacy in Iran before completing his master's and PhD in the Department of Cellular and Molecular Medicine at the University of Ottawa under Mario Tiberi, where he investigated D1 dopamine receptor desensitization by GRK2 and GRK3.

He went on to teach pharmacy and continue GPCR research at an institute for higher education, where his group built 7TMR RAFT, an open database of GPCRs associated with lipid rafts and caveolae. He remains affiliated with that institution, and his current research uses molecular docking to design higher affinity ligands for bitter taste receptors.

Scientific Themes of the Conversation

- Exceptions to the classical paradigm of GPCR phosphorylation and desensitization

- Compartmentalization of GPCR signaling in lipid rafts and caveolae

- Membrane lipid composition as a variable in receptor function and disease

- Computational prediction and the necessity of wet lab validation

- Extraoral bitter taste receptors as potential drug targets

- Mentorship, teaching, and the pleasure of finding out

Key Insights from the Conversation

Losing phosphorylation did not mean losing desensitization

Using serial deletions of the D1 receptor's cytoplasmic tail, Sedaghat found that a phosphorylation deficient receptor still desensitized, and even more strongly than the wild type. For him, results like this are a reminder that even the most basic steps of GPCR regulation are not fully understood.

GRK2 and GRK3 are not interchangeable

The two kinases are closely related and often treated as doing the same job. In HEK293 cells, however, they produced clearly different desensitization profiles for the D1 receptor, which means kinase identity matters when interpreting regulation data.

Where a receptor sits shapes what it signals

Lipid rafts can segregate signaling proteins from their partners. Sedaghat points to Mark Rasenick's work showing that G alpha is sequestered in rafts in depression and released by antidepressants, restoring beta adrenergic signaling, along with efforts to use G alpha fractionation in lymphocytes as a readout of antidepressant action.

An experiment that refused to work

Sedaghat's team gave mice high doses of atorvastatin to deplete membrane cholesterol and looked for signs of depression in a forced swim test. Nothing changed. The lesson he took is that neurons defend their lipid composition robustly, and that genetic approaches may be needed where pharmacological tools fall short.

Computation proposes, the wet lab decides

Molecular dynamics simulations can vary cholesterol content virtually, and AlphaFold has helped close a structural gap that once stretched from rhodopsin to the beta 2 adrenergic receptor. Sedaghat cautions that extrapolating from these models requires care, because every prediction still has to be tested in the lab.

A taste receptor with a place in oncology

Bitter taste receptors are expressed in the brain, gut, lung, and blood vessels, and their activation can induce apoptosis. Sedaghat's group is using databases of natural bitter compounds and molecular docking to design higher affinity ligands, both as research tools and as possible starting points for drug discovery.

Focus, patience, and a formative mentor

Sedaghat credits Tiberi with shaping the way he thinks as a scientist. His advice to junior researchers draws on Richard Feynman's "pleasure of finding out" and Robert Lefkowitz's four keys to success, three of which are focus, along with discipline, respect, patience, and staying a perpetual student.

Episode Timeline

Timestamps were generated using AI for readability.

- 00:00 Introduction

- 02:23 A homemade electroscope and a book of scientist biographies

- 05:22 When pharmacology textbooks listed the mechanism as unknown

- 08:37 D1 desensitization and why GRK2 and GRK3 differ

- 10:16 The phosphorylation deficient receptor that desensitized better

- 13:00 Building the 7TMR RAFT database and lipid rafts in depression

- 16:32 A retreat DVD, and the cholesterol experiment that did not work

- 21:26 Molecular dynamics, AlphaFold, and the wet lab test

- 25:52 Bitter taste receptors far beyond the tongue

- 29:54 Aha moments, mentorship, and advice for junior scientists

Selected Quotes

"The receptor, when it's phosphorylation deficient, with no phosphorylation, is still desensitized, even better than the wild type."

"We still think we know everything about GPCRs, even the basic stuff, even the classical paradigm. But it's been cracking for many years. There are exceptions in every step of GPCR signaling."

"Receptors for sensing bitter taste, you can use them for cancer. Nobody could think of that."

"At the end of the day, you have to go in the lab and test everything and see if it's real or not."

Guest Links

- LinkedIn: https://www.linkedin.com/in/keyvan-sedaghat-phd-54447339/

- 7TMR RAFT Database: https://www.7tmr-raft.org/